GoodRx (NASDAQ:GDRX) Sets New 52-Week Low – Here’s What Happened

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) reached a new 52-week low on Monday . The company traded as low as $3.28 and last traded at $3.2850, with a volume of 686649 shares changing hands. The stock had previously closed at $3.37.

Analyst Ratings Changes

A number of analysts recently issued reports on GDRX shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $6.00 price target on shares of GoodRx in a research report on Monday, August 11th. Raymond James Financial downgraded GoodRx from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 8th. Finally, Weiss Ratings downgraded GoodRx from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GoodRx currently has an average rating of “Hold” and a consensus target price of $5.80.

GoodRx Stock Performance

The firm has a market capitalization of $1.14 billion, a P/E ratio of 32.65, a P/E/G ratio of 1.47 and a beta of 1.20. The firm has a 50-day moving average price of $4.13 and a two-hundred day moving average price of $4.32. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21.

GoodRx (NASDAQ:GDRX) last released its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The business had revenue of $203.07 million for the quarter, compared to the consensus estimate of $205.72 million. During the same quarter last year, the business posted $0.08 earnings per share. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. On average, analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of GoodRx stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total transaction of $95,084.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.17% of the company’s stock.

Institutional Trading of GoodRx

Institutional investors and hedge funds have recently made changes to their positions in the business. Citizens Financial Group Inc. RI bought a new stake in shares of GoodRx during the first quarter worth $44,000. Cetera Investment Advisers bought a new stake in shares of GoodRx in the second quarter valued at about $50,000. Walled Lake Planning & Wealth Management LLC bought a new stake in shares of GoodRx in the second quarter valued at about $55,000. Jump Financial LLC bought a new stake in shares of GoodRx in the first quarter valued at about $49,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of GoodRx by 202.3% in the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after acquiring an additional 7,580 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.